SNG001 Can Safely Improve Lung Function in COPD Patients With Viral Infections, Interim Data Show

SNG001 Can Safely Improve Lung Function in COPD Patients With Viral Infections, Interim Data Show
Synairgen's anti-viral therapy SNG001 has a good safety profile in people with chronic obstructive pulmonary disease (COPD), Phase 2 trial data show. The data also indicate that SNG001 induces its intended anti-viral effect, and that it improves lung function in COPD patients with viral lung infections. "These interim data from our first trial of SNG001 in COPD show that SNG001 could be a valuable novel therapeutic for exacerbating COPD patients," Richard Marsden, CEO of Synairgen, said in a press release. Viral infections — such as the common cold or the flu — can aggravate COPD symptoms. Such infections are found in more than half of COPD exacerbations (when symptoms suddenly worsen or "flare up"). "COPD exacerbations are the second most common cause of unplanned hospitalisation in England, behind cardiovascular diseas
Subscribe or log in to read the rest of this content.